Thetford Mines, August 28, 2018 – KDA Group Inc. (TSXV: KDA) (“KDA Group” or the “Corporation”) announced on June 1st, 2018 an agreement with ZoomMed Inc. (TSXV: ZMD) (“ZoomMed”) whereby KDA Group could have obtained the rights to distribute, under a non-exclusive license, the ZRx Prescriber developed by ZoomMed in the United States.
- LETTER FROM THE PRESIDENT
- KDA Group selected for 2020 TSX venture top 50 list
- kDa Group develops a technological platform for its subsidiary AlliancePharma
- kDa Group develops a cannabis-based medical products eduction program for pharmacists and technicians
- Expansion of the CanNorth Medic plant for cannabis-based medical products